TAK-831 Oral Suspension + TAK-831 Placebo + TAK-831 Tablet
Phase 1Terminated 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia, Cerebellar Ataxia
Conditions
Schizophrenia, Cerebellar Ataxia
Trial Timeline
Sep 23, 2015 → Jul 12, 2016
NCT ID
NCT02566759About TAK-831 Oral Suspension + TAK-831 Placebo + TAK-831 Tablet
TAK-831 Oral Suspension + TAK-831 Placebo + TAK-831 Tablet is a phase 1 stage product being developed by Neurocrine Biosciences for Schizophrenia, Cerebellar Ataxia. The current trial status is terminated. This product is registered under clinical trial identifier NCT02566759. Target conditions include Schizophrenia, Cerebellar Ataxia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02566759 | Phase 1 | Terminated |
Competing Products
20 competing products in Schizophrenia, Cerebellar Ataxia